Financing drug discovery for orphan diseases

Drug Discovery Today

Volumn 19, Issue 5, 2014, Pages 533-538

  Fagnan, David E ^a,b   Gromatzky, Austin A ^a,c   Stein, Roger M ^a,d   Fernandez, Jose Maria ^a   Lo, Andrew W ^a,b,e  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^d State Street Global Exchange ^*  (United States)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORPHAN DRUG;

DRUG APPROVAL; DRUG COST; DRUG RESEARCH; FINANCIAL MANAGEMENT; FUNDING; REVIEW; SIMULATION; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; DRUG MANUFACTURE; ECONOMICS; HUMAN; PROCEDURES; RARE DISEASES;

ANIMALS; CAPITAL FINANCING; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; FUND RAISING; HUMANS; ORPHAN DRUG PRODUCTION; RARE DISEASES;

EID: 84901505771     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.11.009     Document Type: Short Survey

References (24)

1. J.-M. Fernandez et al. Commercializing biomedical research through securitization techniques Nat. Biotechnol. 30 2012 964 975
2. D. Fagnan et al. Can financial engineering cure cancer? Am. Econ. Rev. 103 2013 406 411
3. 107th Congress Rare Disease Act of 2002. Public Law No: 2002 107-280
4. Premier Research The science of hope: the need, the challenges and three proven strategies for successful orphan drug development 2013 Available at: http://premier-research.com/images/uploads/The -Science-of-Hope-the-need,-the- challanges-and-three-proven
5. M.M. Braun et al. Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years Nat. Rev. Drug Discov. 9 2010 519 522
6. A. Sharma et al. Orphan drug: development trends and strategies J. Pharm. Bioallied Sci. 2 2010 290 299
7. A. Schieppati et al. Why rare diseases are an important medical and social issue Lancet 371 2008 2039 2041
8. M.E. Haffner Adopting orphan drugs: two dozen years of treating rare diseases N. Engl. J. Med. 354 2006 445 447
9. K.N. Meekings et al. Orphan drug development: an economically viable strategy for biopharma R&D Drug Discov. Today 17 2012 660 664
10. M. Hay et al. BioMedTracker Clinical Development Success Rates for Investigational Drugs Pharma Competitive Intelligence Conference 2012
11. P.D. Maher Pharmacogenomics of rare and monogenic disorders N. Cohen, Pharmacogenomics and Personalized Medicine 2008 Humana Press 479 497
12. P. Sansone, and J. Bromberg Targeting the Interleukin-6/Jak/Stat pathway in human malignancies J. Clin. Oncol. 30 2012 1005 1014
13. L. Gold The role for transforming growth factor-beta (TFG-beta) in human cancer Crit. Rev. Oncog. 10 1999 303 360
14. Thomson Reuters The economic power of orphan drugs 2012 Available at: http://thomsonreuters.com/products/ip-science/04-013/1001450.pdf
15. E. Seoane-Vasquez Incentives for orphan drug research and development in the United States Orphanet. J. Rare Dis. 3 2008 33
16. S. Harrington Cost of capital for pharmaceutical, biotechnology, and medical device firms P. Danzon, S. Nicholson, The Oxford Handbook of the Economics of the Biopharmaceutical Industry 2012 Oxford University Press 75-99
17. S.M. Paul et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge Nat. Rev. Drug Discov. 9 2010 203 214
18. K.I. Kaitin, and J.A. DiMasi Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009 Clin. Pharm. Ther. 89 2010 183 188
19. J.A. DiMasi et al. Trends in risk associated with new drug development: success rates for investigational drugs Clin. Pharm. Ther. 87 2010 272 277
20. M. Orfali et al. Raising orphans: how clinical development programs of drugs for rare and common diseases are different Clin. Pharm. Ther. 92 2012 262 264
21. M. Mathieu PAREXEL Biopharmaceutical Statistical Sourcebook 2009-2010 2009 Barnett International
22. G.P. Pisano The Promise, the Reality, and the Future of Biotech 2006 Harvard Business School Press
23. G.P. Pisano The evolution of science-based business: innovating how we innovate Ind. Corp. Change 19 2010 465 482
24. S. Papadopoulos Profile: Stelios Papadopoulos Nat. Biotechnol. 29 2012 184